eResearchTechnology, Inc. Sustainability Profile
eResearchTechnology, Inc., commonly known as ERT, is a leading provider of technology and services for the pharmaceutical and biotechnology industries. Headquartered in the United States, ERT operates across major regions, including Europe and Asia, delivering innovative solutions that enhance clinical trial processes. Founded in 1977, the company has achieved significant milestones, including the integration of advanced data collection technologies. ERT's core offerings encompass cardiac safety, respiratory, and eSource solutions, distinguished by their commitment to accuracy and reliability. The company is recognised for its robust market position, having supported thousands of clinical trials globally. With a focus on improving patient outcomes and streamlining trial efficiency, ERT continues to set industry standards in clinical research technology.
DitchCarbon Score
How does eResearchTechnology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
eResearchTechnology, Inc.'s score of 43 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
eResearchTechnology, Inc.'s reported carbon emissions
eResearchTechnology, Inc., headquartered in the US, has not publicly disclosed any specific carbon emissions data. However, the company has made significant climate commitments through its parent company, Clario Holdings, Inc. Clario has set ambitious targets to achieve net-zero greenhouse gas emissions across its value chain by 2045. The near-term targets include a reduction of absolute Scope 1 and 2 greenhouse gas emissions by approximately 63.6% by 2030, using 2021 as the baseline year. Additionally, Clario aims to reduce absolute Scope 3 emissions by about 25% within the same timeframe. For the long term, Clario has committed to an overall reduction of 90% in absolute emissions across all scopes (1, 2, and 3) by 2045. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to meet the requirements necessary to limit global warming to 1.5°C. The commitments reflect a strong dedication to sustainability and climate action within the pharmaceutical, biotechnology, and life sciences sector.
How Carbon Intensive is eResearchTechnology, Inc.'s Industry?
How Carbon Intensive is eResearchTechnology, Inc.'s Location?
eResearchTechnology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
eResearchTechnology, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
